Eiken Chemical (4549) · InitiativeFirst statedLatest Other Disclosures (2026-07-29): "Advanced"
Use and Expansion of Fecal Calprotectin Testing in Crohn’s Disease
First written in FY2026. 1 of 2 entries say "Advanced", first in 2026-07-29. Latest entry: 2026-07-29.
2entries
1years
1from disclosures
How it moved
Same theme, other companies
Post-approval adoption and overseas expansion of a fecal calprotectin assayA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-07-29AdvancedOther Disclosures
「Analytes: hemoglobin, calprotectin, transferrin」
The planned launch of an analyser capable of measuring fecal calprotectin made the product-development theme more specific. - FY2026First statedAnnual report
「In 2023, the Company obtained regulatory approval for the use of its fecal calprotectin measurement reagent to assist in understanding the disease state of Crohn's disease, including its clinical significance. This has increased recognition of the test in clinical settings as a new non-invasive stool-testing option for assessing Crohn's disease, and adoption by medical institutions in Japan continued to expand steadily during the current consolidated fiscal year.」
Following regulatory approval of the fecal calprotectin measurement reagent for use in assessing the disease state of Crohn's disease, the Company identified its expanding adoption by medical institutions in Japan and growing clinical use overseas, particularly in Europe and the United States, as a new healthcare product theme.